Cellectar to release top-line WM pivotal data at JP Morgan Conference week of Jan 8, 2024; raises up to $102.9M via PIPE

Cellectar Biosciences, Inc.

Top-line data from Waldenstrom's macroglobulinemia pivotal trial to be released week of Jan 8, 2024 at JP Morgan Healthcare Conference.
Closed PIPE with up to $102.9M gross proceeds (milestone-based); initial $24.5M at $1.82/share; led by Rosalind Advisors.
Received EMA PRIME designation for iopofosine I 131 in WM after two or more prior treatments.
Cash of $19.0M at Sep 30; net $22.2M from PIPE; believes funded into Q2 2024.
Q3 R&D expense $7.3M (up from $5.4M YoY); G&A $2.1M (down from $2.4M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cellectar Biosciences, Inc. reported preliminary financial results for three months ended September 30, 2023.

Period: three months ended September 30, 2023
Result: preliminary results

Exact text from the filing

On November 2, 2023, we issued a press release announcing preliminary financial results for the three months ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-113593

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.